Design Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Design Therapeutics, Inc. reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -30 cents. The mean expectation of eight analysts for the quarter was for a loss of 35 cents per share. Wall Street expected results to range from -39 cents to -30 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Design Therapeutics, Inc.'s reported EPS for the quarter was a loss of 32 cents​.

• The company reported a quarterly loss of $20.29 million.

• Design Therapeutics, Inc. shares had fallen by 17.7% this quarter and gained 10.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Design Therapeutics, Inc. is $21.00, about 50.8% above its last closing price of $10.34

This summary was machine generated from LSEG data November 4 at 09:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)